Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Barter

Showing results (61-70 of 390) with videos related to

Pageof 39
Sort By:
Biochimica Et Biophysica Acta|July 20, 1982
An effect of very low density lipoproteins on the rate of cholesterol esterification in human plasmaG J Hopkins, P J Barter
Arteriosclerosis, Thrombosis, and Vascular Biology|August 25, 2007
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?Philip J Barter, Kerry-Anne Rye
Pharmacological Reviews|March 18, 2016
New Era of Lipid-Lowering DrugsPhilip J Barter, Kerry-Anne Rye
Journal of Clinical Lipidology|May 22, 2018
Variations in time to benefit among clinical trials of cholesterol-lowering drugsPhilip J Barter, David D Waters
Biochimica Et Biophysica Acta|June 6, 1984
Capacity of lipoproteins to act as substrates for lecithin:cholesterol acyltransferase. Enhancement by pre-incubation with an artificial triacylglycerol emulsionG J Hopkins, P J Barter
Journal of Lipid Research|August 1, 1996
Formation of new HDL particles from lipid-free apolipoprotein A-IM A Clay, P J Barter
Atherosclerosis|March 1, 1996
High density lipoproteins and coronary heart diseaseP J Barter, K A Rye
European Heart Journal|May 20, 2017
HDL cholesterol concentration or HDL function: which matters?Philip J Barter, Kerry-Anne Rye
Cardiology Clinics|April 4, 2018
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease RiskPhilip J Barter, Kerry-Anne Rye
Journal of Lipid Research|April 13, 2012
The inhibition of cholesteryl ester transfer protein: a long and winding roadKerry-Anne Rye, Philip J Barter
Pageof 39

Showing results (61-70 of 390) with videos related to

Sort By:
Pageof 39
Biochimica Et Biophysica Acta|July 20, 1982
An effect of very low density lipoproteins on the rate of cholesterol esterification in human plasmaG J Hopkins, P J Barter
Arteriosclerosis, Thrombosis, and Vascular Biology|August 25, 2007
Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?Philip J Barter, Kerry-Anne Rye
Pharmacological Reviews|March 18, 2016
New Era of Lipid-Lowering DrugsPhilip J Barter, Kerry-Anne Rye
Journal of Clinical Lipidology|May 22, 2018
Variations in time to benefit among clinical trials of cholesterol-lowering drugsPhilip J Barter, David D Waters
Biochimica Et Biophysica Acta|June 6, 1984
Capacity of lipoproteins to act as substrates for lecithin:cholesterol acyltransferase. Enhancement by pre-incubation with an artificial triacylglycerol emulsionG J Hopkins, P J Barter
Journal of Lipid Research|August 1, 1996
Formation of new HDL particles from lipid-free apolipoprotein A-IM A Clay, P J Barter
Atherosclerosis|March 1, 1996
High density lipoproteins and coronary heart diseaseP J Barter, K A Rye
European Heart Journal|May 20, 2017
HDL cholesterol concentration or HDL function: which matters?Philip J Barter, Kerry-Anne Rye
Cardiology Clinics|April 4, 2018
Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease RiskPhilip J Barter, Kerry-Anne Rye
Journal of Lipid Research|April 13, 2012
The inhibition of cholesteryl ester transfer protein: a long and winding roadKerry-Anne Rye, Philip J Barter
Pageof 39